CellaVision AB (publ) (CEVI.ST) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. CEVI.ST files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.68% | 30.00% | Pass |
| Interest-bearing investments | 4.96% | 30.00% | Pass |
| Non-permissible income | 0.14% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.34% | 33.00% | Pass |
| Interest-bearing investments | 17.19% | 33.00% | Pass |
| Non-liquid assets | 71.82% | at least 20.00% | Pass |
| Non-permissible income | 0.14% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.34% | 33.33% | Pass |
| Cash + interest-bearing securities | 17.19% | 33.33% | Pass |
| Accounts receivable | 28.18% | 33.33% | Pass |
| Non-permissible income | 0.14% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.34% | 33.33% | Pass |
| Cash + interest-bearing securities | 17.19% | 33.33% | Pass |
| Accounts receivable | 28.18% | 50.00% | Pass |
| Non-permissible income | 0.14% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.62% | 33.00% | Pass |
| Cash + interest-bearing securities | 4.57% | 33.00% | Pass |
| Accounts receivable | 2.92% | 33.00% | Pass |
| Non-permissible income | 0.14% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.59% | 33.00% | Pass |
| Cash + interest-bearing securities | 4.31% | 49.00% | Pass |
| Accounts receivable | 2.76% | 49.00% | Pass |
| Non-permissible income | 0.14% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.59% | 33.33% | Pass |
| Cash + interest-bearing securities | 4.31% | 33.33% | Pass |
| Accounts receivable | 7.06% | 49.00% | Pass |
| Non-permissible income | 0.14% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 56.10 | NEUTRAL |
| Stochastic %K (14) | 32.84 | NEUTRAL |
| CCI (20) | -26.33 | NEUTRAL |
| Williams %R (14) | -67.16 | NEUTRAL |
| MACD (12,26,9) | -1.11 | SELL |
| ROC (10) | -2.06 | SELL |
| Momentum (10) | -3.40 | SELL |
| EMA (10) | 161.38 | BUY |
| SMA (10) | 162.38 | SELL |
| EMA (20) | 159.87 | BUY |
| SMA (20) | 161.28 | BUY |
| EMA (30) | 157.40 | BUY |
| SMA (30) | 157.67 | BUY |
| EMA (50) | 152.95 | BUY |
| SMA (50) | 151.11 | BUY |
| EMA (100) | 148.10 | BUY |
| SMA (100) | 139.95 | BUY |
| EMA (200) | 151.05 | BUY |
| SMA (200) | 144.95 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Medical Devices
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.